Telesis Bio Inc. TBIO
0.00
(0.01)
(100.00%)
as of 25 Sep
- Market cap
- $5.3M
- P/E
- 0.0×
Follow TBIO
Growth Flags
show if company had growth for consecutive years
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.43 | 0.53 | 0.35 | 0.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.61) | (4.05) | (1.25) | (0.98) | |
P/B ratio |
49.44 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(0.08) | 0.11 | 0.09 | 0.51 | |
EV/EBITDA |
0.07 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.06 | (0.10) | (0.08) | (0.37) | |
EV/FCF |
0.06 | (0.10) | (0.08) | (0.35) | |
Quick Ratio |
3.02 | 2.92 | 1.45 | 0.89 | |
Current Ratio |
3.71 | 3.65 | 1.89 | 1.23 | |
Net Debt/EBITDA |
2.46 | 1.42 | 0.46 | (0.35) | |
Debt/Assets |
7.69% | 8.44% | 10.21% | 25.19% | |
Debt/Equity |
22.76 | (0.65) | (0.26) | (0.23) | |
Asset Turnover |
0.36 | 0.32 | 0.23 | 0.26 | |
Operating CF/Net income |
0.40 | 0.35 | 0.41 | 0.96 | |
Capex/Depreciation |
(0.03) | (0.41) | (0.09) | (0.07) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
50.78% | 85.03% | 159.35% | 138.83% | |
Selling, General and Administrative Expense of Revenue |
80.98% | 204.71% | 464.84% | 254.09% | |
Intangible Assets out of Total Assets |
0.06 | 0.07 | 0.08 | 0.17 | |
Share Based Compensation of Revenue |
6.10% | 22.27% | 56.06% | 36.14% | |
Graham Net Nets |
(3.38) | (3.68) | (8.70) | (6.46) | |
Graham Number |
0.00 | 55.90 | 90.65 | 98.70 | |
Earnings Yield |
(413.49%) | (359.46%) | (797.04%) | (736.32%) | |
Free Cash Flow Yield |
(311.30%) | (219.33%) | (341.10%) | (351.16%) | |
Revenue per Share |
6.08 | 2.06 | 0.90 | 0.88 | |
Operating CF per Share |
(4.42) | (1.94) | (3.09) | (3.92) | |
Capex per Share |
(0.20) | (0.30) | (0.05) | (0.03) | |
Free Cash Flow per Share |
(4.62) | (2.24) | (3.14) | (3.96) | |
Cash per Share |
11.65 | 9.39 | 5.96 | 2.60 | |
Shareholders Equity per Share |
0.14 | (4.93) | (11.87) | (15.35) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.14 | (4.93) | (11.87) | (15.35) | |
Free Cash Flow |
(7.67) | (3.74) | (5.43) | (7.01) | |
Working Capital |
22.17 | 16.98 | 7.14 | 1.49 | |
Capital Expenditures |
(0.34) | (0.50) | (0.08) | (0.05) | |
Net Current Asset Value |
(39.82) | (48.17) | (58.11) | (43.84) | |
EV/EBIT |
0.05 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.15 | 0.05 | 0.04 | |
Net Profit Margin |
(181.01%) | (268.08%) | (850.39%) | (463.41%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.63 | 4.42 | 4.79 | 3.31 | |
Average Payables |
2.23 | 2.17 | 1.48 | 1.95 | |
Average Inventory |
2.96 | 2.98 | 2.61 | 2.68 | |
Average Assets |
75.89 | 76.25 | 83.63 | 64.88 | |
Average Common Equity |
23.40 | 14.19 | 3.69 | (4.73) |
Columns are period end dates